Penumbra Inc
PEN316.050USD
+0.700+0.22%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
12.37BMarket Cap
74.75P/E TTM
More Details of Penumbra Inc Company
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Penumbra Inc Info
Ticker SymbolPEN
Company namePenumbra Inc
IPO dateSep 18, 2015
CEOElsesser (Adam)
Number of employees4500
Security typeOrdinary Share
Fiscal year-endSep 18
AddressOne Penumbra Place
CityALAMEDA
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code94502
Phone15109952486
Websitehttps://www.penumbrainc.com/
Ticker SymbolPEN
IPO dateSep 18, 2015
CEOElsesser (Adam)
Company Executives of Penumbra Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Adam Elsesser, J.D.
Mr. Adam Elsesser, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.02M
+1.21%
Dr. Arani Bose, M.D.
Dr. Arani Bose, M.D.
Director
Director
290.26K
-3.97%
Ms. Johanna Roberts
Ms. Johanna Roberts
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
51.26K
-1.73%
Mr. Lambert Shiu
Mr. Lambert Shiu
Chief Accounting Officer
Chief Accounting Officer
28.34K
+10.65%
Ms. Shruthi Narayan
Ms. Shruthi Narayan
President
President
26.60K
-1.33%
Ms. Janet Leeds
Ms. Janet Leeds
Independent Director
Independent Director
5.49K
-1.06%
Ms. Bridget O'Rourke
Ms. Bridget O'Rourke
Independent Director
Independent Director
4.82K
-1.03%
Ms. Surbhi Sarna
Ms. Surbhi Sarna
Independent Director
Independent Director
3.15K
-1.84%
Ms. Maggie S. Yuen
Ms. Maggie S. Yuen
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Thomas C. (Tom) Wilder, III
Mr. Thomas C. (Tom) Wilder, III
Presiding Independent Director
Presiding Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Adam Elsesser, J.D.
Mr. Adam Elsesser, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.02M
+1.21%
Dr. Arani Bose, M.D.
Dr. Arani Bose, M.D.
Director
Director
290.26K
-3.97%
Ms. Johanna Roberts
Ms. Johanna Roberts
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
51.26K
-1.73%
Mr. Lambert Shiu
Mr. Lambert Shiu
Chief Accounting Officer
Chief Accounting Officer
28.34K
+10.65%
Ms. Shruthi Narayan
Ms. Shruthi Narayan
President
President
26.60K
-1.33%
Ms. Janet Leeds
Ms. Janet Leeds
Independent Director
Independent Director
5.49K
-1.06%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Thrombectomy
230.26M
67.83%
Embolization and Access
109.20M
32.17%
By RegionUSD
Name
Revenue
Proportion
United States
260.82M
76.83%
International
78.64M
23.17%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Thrombectomy
230.26M
67.83%
Embolization and Access
109.20M
32.17%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.02%
The Vanguard Group, Inc.
9.77%
BlackRock Institutional Trust Company, N.A.
9.14%
T. Rowe Price Associates, Inc.
4.49%
State Street Investment Management (US)
2.97%
Other
60.60%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.02%
The Vanguard Group, Inc.
9.77%
BlackRock Institutional Trust Company, N.A.
9.14%
T. Rowe Price Associates, Inc.
4.49%
State Street Investment Management (US)
2.97%
Other
60.60%
Shareholder Types
Shareholders
Proportion
Investment Advisor
61.63%
Investment Advisor/Hedge Fund
23.62%
Hedge Fund
7.37%
Individual Investor
3.72%
Research Firm
1.96%
Pension Fund
1.65%
Sovereign Wealth Fund
1.20%
Private Equity
0.56%
Bank and Trust
0.43%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
852
37.12M
94.79%
-3.14M
2025Q2
864
37.32M
95.72%
-2.83M
2025Q1
878
36.92M
95.33%
-3.44M
2024Q4
834
37.02M
96.10%
-3.78M
2024Q3
813
37.33M
96.12%
-2.93M
2024Q2
796
37.57M
96.93%
+395.13K
2024Q1
777
35.67M
92.18%
-2.09M
2023Q4
759
36.33M
94.13%
-67.98K
2023Q3
737
35.15M
91.46%
-2.09M
2023Q2
719
36.20M
94.64%
-1.94M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
5.04M
12.92%
+93.97K
+1.90%
Jun 30, 2025
The Vanguard Group, Inc.
3.85M
9.88%
+185.31K
+5.05%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.61M
9.25%
+78.78K
+2.23%
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.34M
3.44%
+164.55K
+13.99%
Jun 30, 2025
State Street Investment Management (US)
1.17M
3%
-26.92K
-2.25%
Jun 30, 2025
Elsesser (Adam)
1.02M
2.62%
+12.18K
+1.21%
Sep 03, 2025
Baillie Gifford & Co.
922.13K
2.36%
+233.13K
+33.84%
Jun 30, 2025
RTW Investments L.P.
863.55K
2.21%
+783.00
+0.09%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Motley Fool Small-Cap Growth ETF
2.77%
Congress SMid Growth ETF
1.99%
First Trust Indxx Medical Devices ETF
1.75%
Simplify Health Care ETF
1.54%
State Street SPDR S&P Health Care Equipment ETF
1.49%
ROBO Global Healthcare Technology & Innovation ETF
1.46%
Future Fund Long/Short ETF
1.42%
Invesco S&P MidCap Quality ETF
1.4%
Putnam Sustainable Future ETF
1.25%
Invesco S&P MidCap Momentum ETF
1.09%
View more
Motley Fool Small-Cap Growth ETF
Proportion2.77%
Congress SMid Growth ETF
Proportion1.99%
First Trust Indxx Medical Devices ETF
Proportion1.75%
Simplify Health Care ETF
Proportion1.54%
State Street SPDR S&P Health Care Equipment ETF
Proportion1.49%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.46%
Future Fund Long/Short ETF
Proportion1.42%
Invesco S&P MidCap Quality ETF
Proportion1.4%
Putnam Sustainable Future ETF
Proportion1.25%
Invesco S&P MidCap Momentum ETF
Proportion1.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Penumbra Inc?
The top five shareholders of Penumbra Inc are:
Fidelity Management & Research Company LLC holds 5.04M shares, accounting for 12.92% of the total shares.
The Vanguard Group, Inc. holds 3.85M shares, accounting for 9.88% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.61M shares, accounting for 9.25% of the total shares.
T. Rowe Price Associates, Inc. holds 1.34M shares, accounting for 3.44% of the total shares.
State Street Investment Management (US) holds 1.17M shares, accounting for 3.00% of the total shares.
Fidelity Management & Research Company LLC holds 5.04M shares, accounting for 12.92% of the total shares.
The Vanguard Group, Inc. holds 3.85M shares, accounting for 9.88% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.61M shares, accounting for 9.25% of the total shares.
T. Rowe Price Associates, Inc. holds 1.34M shares, accounting for 3.44% of the total shares.
State Street Investment Management (US) holds 1.17M shares, accounting for 3.00% of the total shares.
What are the top three shareholder types of Penumbra Inc?
The top three shareholder types of Penumbra Inc are:
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Penumbra Inc (PEN)?
As of 2025Q3, 852 institutions hold shares of Penumbra Inc, with a combined market value of approximately 37.12M, accounting for 94.79% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.93%.
What is the biggest source of revenue for Penumbra Inc?
In FY2025Q2, the Thrombectomy business generated the highest revenue for Penumbra Inc, amounting to 230.26M and accounting for 67.83% of total revenue.
